First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial
一线替雷利珠单抗联合化疗治疗复发或转移性鼻咽癌:RATIONALE-309 III期随机临床试验的三年随访
期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2026.0020
Yang, Yunpeng; Yen, Chia-Jui; Pan, Jianji; Wang, Hui; Qu, Shenhong; Chen, Nianyong; Chen, Xiaozhong; Sun, Yan; He, Xiaohui; Hu, Chaosu; Lin, Lizhu; Wu, Yanjie; Yuan, Shuai; Chen, Chenqi; Xu, Xingxing; Ma, Xiaopeng; Leaw, Shiangjiin; Zhang, Li; Fang, Wenfeng